Screening in survivors at AVERAGE risk of a second malignant neoplasm | ||||
---|---|---|---|---|
Breast | Cervix | Colorectal | Skin | |
USPSTF recommended screening for the general (average risk) population |
Mammogram every 1 to 2 years for women aged 40 years or older |
Papanicolaou smear every 3 years commencing at age 21 years* |
** | Not applicable |
Surveillance in survivors at HIGH risk of a second malignant neoplasm | ||||
---|---|---|---|---|
Breast | Cervix | Colorectal | Skin | |
Definition (COG) of high risk group |
Female, ≥20 Gy radiation therapy to the chest |
Not applicable | ≥30 Gy radiation therapy to the abdomen, pelvis or spine |
Any radiation therapy |
COG recommended surveillance for survivors at high risk |
Annual mammogram beginning 8 years after radiation or age 25 years, whichever occurs last*** |
Not applicable | Colonoscopy every 5 years beginning at age 35 years |
Annual dermatologic exam of irradiated areas |
Guideline recommends Papanicolaou smear screening to start at time of first sexual intercourse or age 21 years, whichever is earlier (http://www.ahrq.gov/clinic/3rduspstf/cervcan/cervcanrr.htm). Since time of first intercourse was not captured by the study questionnaire, we used age 21 years as the expected time of the commencement of screening.
Since few survivors in the cohort have reached the age at which colorectal cancer screening in the general population is recommended, this outcome is not presented in this analysis
Breast MRI was identified as an adjunct to mammography in a revised version of the COG surveillance guidelines published in 2008 after the completion of the study surveys.
MRI is not assessed in this analysis.